Oxford Biomedica (OXB) Share Price

Health Care Sector

  1. Home
    2. /
  2. Company
    3. /
  3. Oxford Biomedica

NOTE: This is based on 135 open tips for Oxford Biomedica (OXB)


Oxford Biomedica (OXB)
Latest Quote Price

301.00p

Oxford Biomedica (OXB)
Price Change (%)

3.45%


Latest Bid : 299.50p Latest Ask : 302.00p
High Today : 305.00p Low Today : 282.00p
This Years High : 445.00p This Years Low : 190.40p
Volume : 179,518 MKT Cap : £316.05M
Trading Velocity : Premium Only Activity Score : Premium Only
Consensus Score : Premium Only Momentum Score : Premium Only

Stock Splits and Consolidations

30/05/2018 – Stock Consolidation 50.000:1.000


Oxford Biomedica (OXB) Overview

Oxford Biomedica develops innovative new IP-protected , LentiVector® based therapies, leveraging our internal research expertise and know-how. We select patient-centric product candidates and progress these through proof-of-concept, and into early clinical development, before either seeking third-party funding for full development and commercialisation or to develop further in-house.

Oxford Biomedica (OXB) Latest Tips

Type Tipster SectorScore Start date Performance
Buy Mark David Hartley Premium Only 2025-03-05 01:40:00 05/03/2025 -0.50%
Neutral JP Morgan Premium Only 2024-12-03 05:25:00 03/12/2024 –
Neutral JP Morgan Premium Only 2024-10-28 04:58:00 28/10/2024 –
Hold Deutsche Bank Premium Only 2024-09-24 16:46:00 24/09/2024 0.13%
Outperform RBC Capital Premium Only 2024-05-21 15:16:00 21/05/2024 -10.01%

Premium Content

You are missing Premium Content from this chart

Please Log In to a premium account or Sign Up today to view premium content.


Oxford Biomedica (OXB) Active Short Positions

Fund Manager Position Date
Arrowstreet Capital, Limited Partnership 0.6% 28/03/2025

See more short positions...


Latest Bid : 299.50p Latest Ask : 302.00p
High Today : 305.00p Low Today : 282.00p
This Years High : 445.00p This Years Low : 190.40p
Volume : 179,518 MKT Cap : £316.05M

Oxford Biomedica Overview

Oxford Biomedica develops innovative new IP-protected , LentiVector® based therapies, leveraging our internal research expertise and know-how. We select patient-centric product candidates and progress these through proof-of-concept, and into early clinical development, before either seeking third-party funding for full development and commercialisation or to develop further in-house.

NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.


Latest Oxford Biomedica Tips

Type Tipster SectorScore Start date Performance
Buy Mark David Hartley Premium Only 2025-03-05 01:40:00 05/03/2025 -0.50%
Neutral JP Morgan Premium Only 2024-12-03 05:25:00 03/12/2024 –
Neutral JP Morgan Premium Only 2024-10-28 04:58:00 28/10/2024 –
Hold Deutsche Bank Premium Only 2024-09-24 16:46:00 24/09/2024 0.13%
Outperform RBC Capital Premium Only 2024-05-21 15:16:00 21/05/2024 -10.01%

Stock Splits and Consolidations

30/05/2018 – Stock Consolidation 50.000:1.000